FDA Approves AngioDynamics' IDE For RELIEF Study Testing NanoKnife In Benign Prostate Hyperplasia

AngioDynamics received FDA approval for an investigational device exemption, allowing its RELIEF study to proceed for the proprietary NanoKnife system. The decision removes a key regulatory hurdle and supports clinical development for the device. The news is positive for the company's product pipeline, but the immediate market impact is likely limited.

Analysis

AngioDynamics received FDA approval for an investigational device exemption, allowing its RELIEF study to proceed for the proprietary NanoKnife system. The decision removes a key regulatory hurdle and supports clinical development for the device. The news is positive for the company's product pipeline, but the immediate market impact is likely limited.